Abstract
Over the last 60 years, poly-ADP-ribose polymerases (PARPs, 17 family members in humans) have emerged as important regulators of physiology and disease. Small-molecule inhibitors have been essential tools for unraveling PARP function, and recently the first PARP inhibitors have been approved for the treatment of various human cancers. However, inhibitors have only been developed for a few PARPs and in vitro profiling has revealed that many of these exhibit polypharmacology across the PARP family. In this review, we discuss the history, development, and current state of the field, highlighting the limitations and opportunities for PARP inhibitor development.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 211-231 |
| Number of pages | 21 |
| Journal | Current Topics in Microbiology and Immunology |
| Volume | 420 |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
ASJC Scopus subject areas
- Immunology and Allergy
- Microbiology
- Immunology
- Microbiology (medical)
Cite this
Small-Molecule Inhibitors of PARPs : From Tools for Investigating ADP-Ribosylation to Therapeutics. / Kirby, Ilsa T.; Cohen, Michael.
In: Current Topics in Microbiology and Immunology, Vol. 420, 01.01.2019, p. 211-231.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Small-Molecule Inhibitors of PARPs
T2 - From Tools for Investigating ADP-Ribosylation to Therapeutics
AU - Kirby, Ilsa T.
AU - Cohen, Michael
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Over the last 60 years, poly-ADP-ribose polymerases (PARPs, 17 family members in humans) have emerged as important regulators of physiology and disease. Small-molecule inhibitors have been essential tools for unraveling PARP function, and recently the first PARP inhibitors have been approved for the treatment of various human cancers. However, inhibitors have only been developed for a few PARPs and in vitro profiling has revealed that many of these exhibit polypharmacology across the PARP family. In this review, we discuss the history, development, and current state of the field, highlighting the limitations and opportunities for PARP inhibitor development.
AB - Over the last 60 years, poly-ADP-ribose polymerases (PARPs, 17 family members in humans) have emerged as important regulators of physiology and disease. Small-molecule inhibitors have been essential tools for unraveling PARP function, and recently the first PARP inhibitors have been approved for the treatment of various human cancers. However, inhibitors have only been developed for a few PARPs and in vitro profiling has revealed that many of these exhibit polypharmacology across the PARP family. In this review, we discuss the history, development, and current state of the field, highlighting the limitations and opportunities for PARP inhibitor development.
UR - http://www.scopus.com/inward/record.url?scp=85059827534&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059827534&partnerID=8YFLogxK
U2 - 10.1007/82_2018_137
DO - 10.1007/82_2018_137
M3 - Article
C2 - 30242511
AN - SCOPUS:85059827534
VL - 420
SP - 211
EP - 231
JO - Current Topics in Microbiology and Immunology
JF - Current Topics in Microbiology and Immunology
SN - 0070-217X
ER -